CyclontaneЦиклонтан
What is it?
1-Hydroxy-4-cyclohexylaminoadamantane hydrochloride (ADK-638), an experimental hydroxyadamantane. Individual-compound experiments and the sodium-oxybate formulation are separate evidence.
Research context
1-Hydroxy-4-cyclohexylaminoadamantane hydrochloride (ADK-638), an experimental hydroxyadamantane. Individual-compound experiments and the sodium-oxybate formulation are separate evidence.
What the studies found
animal · 2022
CD-1 mice separated by baseline attention phenotype; three administrations
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
Limit: Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability ↗Patent-reported animal experiment · 2018
Rodent circadian-disruption experiments; 18-hour light/dark schedule
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
Limit: Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human efficacy findings verified in this update
- Study methods
- —Source-specific animal, chemistry, patent or dissertation evidence
- Independent replication
- —Independent replication not established; translations are not separate experiments
- Source access
- —Access and review depth appear with each linked record
- Safety evidence
- —Human safety and interactions not established; animal activity is not a safe-use recommendation
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Chlodantane, Cyclontane and the ADK research programme ↗
Linked sources
Explore the research map and unresolved leads ↗
Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis
Format: Patent · Reviewed: Selected methods and sleep-result passages reviewed
· RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense
The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.
- Population / setting
- Rodent circadian-disruption experiments; 18-hour light/dark schedule
- What was checked
- Selected source passages checked; complete methods and risk of bias not appraised.
Limitations & review scope
- Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
- No clinical sleep benefit or safe self-use regimen follows from these experiments.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed
N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
- Population / setting
- CD-1 mice separated by baseline attention phenotype; three administrations
- What was checked
- Selected source passages checked; complete methods and risk of bias not appraised.
Limitations & review scope
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
- Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Original Cyclontane / ADK-638 patent trail
· RU2196575C2; cited in later RU2674342C2
The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.
- Population / setting
- Original experiments not independently recovered for this entry
- What was checked
- Prior-art citation followed from the 2018 patent; original retrieval unsuccessful.
Limitations & review scope
- Bibliographic lead only; neither potency ratios nor toxicity estimates from secondary accounts are treated as verified here.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Explore related historical combinations ↗
Browse bibliography & PDFs ↗